SCHEMBL24258028

SCHEMBL24258028

Clc1ccc(-c2noc(Cc3cccc4ccccc34)n2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
RAB9A P51151 3/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
KDM4E B2RXH2 4/20 0.43
TDP1 Q9NUW8 4/20 0.43
TSHR P16473 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
MAPK1 P28482 3/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTPN1 P18031 4/20 0.41
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258026 0.87 SMN1; SMN2 (0.43) CASP3SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL26004980 0.85 TSHR (0.48) SMN1; SMN2RAB9AMAPTNPC1KDM4E
SCHEMBL24258043 0.82 S1PR1 (0.59) CASP3SMN1; SMN2RAB9ANPC1TDP1
SCHEMBL24258078 0.79 CYP1A2 (0.50) CASP3SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL24258005 0.78 CYP1A2 (0.51) CASP3SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL24258045 0.76 CYP1A2 (0.66) CASP3SMN1; SMN2RAB9ANPC1TDP1
SCHEMBL24258025 0.74 CYP1A2 (0.53) CASP3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL24258075 0.73 ERCC1 (0.52) CASP3SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3737145 0.73 S1PR1 (0.49) SMN1; SMN2MAPTTSHRL3MBTL1MAPK1
SCHEMBL31378147 0.71 ALDH1A1 (0.46) SMN1; SMN2MAPTKDM4ETDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 CASP3 1299/4885SMN1; SMN2 796/4885RAB9A 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.